Mavacoxib,170569-88-7

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Mavacoxib

CAS No. : 170569-88-7

MCE 国际站：Mavacoxib

产品活性：Mavacoxib 是一种选择性的口服长效环氧合酶 2 (COX-2) 抑制剂，是一种长效的非甾体类抗炎剂 (NSAID)，用于研究犬退化性关节病相关的疼痛和炎症。

研究领域：Immunology/Inflammation

作用靶点：COX

In Vitro: Mavacoxib (0-200 μM; 72 hours; CSKOS, U2OS, REM, K9TCC and T24 cells) treatment reduces cell viability in a dose-dependent manner. However, sensitivity to Mavacoxib varied between the cell lines, with IC₅₀ values ranging from 34.5 μM to 157.7 μM. The IC₅₀ values of U2OS, KTOSA5, CSKOS, REM, LILY, K9TCC, K9TCC-AXA, K9TCC-In, K9TCC-Sh, T24, 5637 and HT-1376 cells are 52.6 μM, 89.8 μM, 106.3 μM, 66.6 μM, 97.5 μM, 54.9 μM, 34.5 μM, 78.7 μM, 50.7 μM, 63.4 μM, 72.5 μM and 157.7 μM, respectively.
Mavacoxib (0-200 μM; 48 hours; KTOSA5, REM, LILY, K9TCC, U2OS, and T24 cells) treatment can induce caspase-dependent apoptosis in a number of cell lines.
Mavacoxib (0-75 μM; 24 hours; CSKOS, U2OS, REM, K9TCC and T24 cells) treatment down-regulates the expression of p-Akt in CSKOS cells in in a dose-dependent manner, as is total Akt in U2OS cells. In REM cells, both p-ERK and p-Akt are increased in expression with increasing doses of Mavacoxib, and in K9TCC cells p-ERK expression is also increased with Mavacoxib treatment.

In Vivo: Osteoarthritic dogs enrolled in the studies are randomized to receive treatment with Mavacoxib and daily placebo for carprofen or placebo for Mavacoxib and daily carprofen at a nominal dose of 4 mg/kg BW. Mavacoxib is administered in both studies with a 2-week interval between the first and second doses but with monthly dosing thereafter. The nominal Mavacoxib doses in Studies 1 and 2 are 4 and 2 mg/kg BW, respectively. Seven Mavacoxib doses are administered in Study 1, but only five doses in Study 2. In Study 1, Mavacoxib is administered without regard to the timing of meals, but in Study 2, all of the Mavacoxib doses are administered with food.

相关产品：Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Anti-Aging Compound Library  |  Pyroptosis Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Colorectal Cancer Compound Library   |  Antidepressant Compound Library  |  Protein-protein Interaction Inhibitor Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Heterocyclic Compound Library  |  Highly Selective Inhibitors Library  |  Acetaminophen  |  Indomethacin  |  Celecoxib  |  EIPA  |  Aspirin  |  Oxidopamine hydrobromide  |  Deferiprone  |  Diclofenac  |  Gallic acid  |  Ibuprofen  |  Catechin  |  20(S)-Ginsenoside Rg3  |  Cucurbitacin B  |  Carprofen  |  Meloxicam  |  (-)-Epicatechin  |  NS-398  |  Naproxen  |  Xanthohumol  |  Flufenamic acid  |  Salicylic acid  |  Phenacetin  |  Ketoprofen  |  SC-560  |  Rebamipide  |  Ginsenoside Rd

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds